Literature DB >> 9052739

Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization.

G Inchauspe1, L Vitvitski, M E Major, G Jung, U Spengler, M Maisonnas, C Trepo.   

Abstract

In a murine model, we have compared humoral and T-helper (Th) responses induced following genetic immunization with two hepatitis C virus (HCV) plasmid-derived immunogens: a plasmid expressing the full-length nucleocapsid (CAP) as a nonsecreted antigen (pCMVC2) and a plasmid expressing the amino-terminal part of CAP as a secreted antigen (pS2S.C2N). In BALB/c mice, intramuscular injection of either plasmid induced IgG2a antibodies associated with a Th1-like profile characterized by the in vitro splenic production of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma). The pS2S.C2N plasmid induced antibody titers three- to five-fold higher than those obtained with the pCMVC2 plasmid (maximal titers 1:1,500 versus 1:500). In control experiments, immunization using purified CAP antigen induced a predominant, but not exclusive, Th2-like profile as determined by the splenic production of IL-4 and IL-10. Six putative Th determinants were identified using a panoply of overlapping synthetic peptides in in vitro stimulation assays: amino acids 20-44, 39-63, 79-113, 89-113, 118-142, and 138-152. For all CAP immunogens, MHC haplotype of immunized mice was found to influence seroconversion rates but not the type of cytokines produced in vitro. H-2d mice were faster responders and displayed recall T-cell activation by a larger number of peptides than H-2b mice, whereas H-2s mice were overall very poor responders. Splenic stimulation by at least one determinant, amino acids 79-103, appeared to be highly specific of the H-2b background and of DNA immunization only. These data indicate that DNA immunogens expressing different forms of HCV-CAP are not associated with different Th profiles but rather different seroconversion rates and antibody titers and that collaboration of distinct T-help epitopes can be restricted by the MHC background.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9052739     DOI: 10.1089/dna.1997.16.185

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  13 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response.

Authors:  P J Lewis; L A Babiuk
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  DNA vaccine construct incorporating intercellular trafficking and intracellular targeting motifs effectively primes and induces memory B- and T-cell responses in outbred animals.

Authors:  Waithaka Mwangi; Wendy C Brown; Gary A Splitter; Christopher J Davies; Chris J Howard; Jayne C Hope; Yoko Aida; Yan Zhuang; Beverly J Hunter; Guy H Palmer
Journal:  Clin Vaccine Immunol       Date:  2007-01-10

Review 4.  Gene vaccination for hepatitis C.

Authors:  G Inchauspé
Journal:  Springer Semin Immunopathol       Date:  1997

5.  Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode.

Authors:  I Nakano; G Maertens; M E Major; L Vitvitski; J Dubuisson; A Fournillier; G De Martynoff; C Trepo; G Inchauspe
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

6.  Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites.

Authors:  A Fournillier; C Wychowski; D Boucreux; T F Baumert; J C Meunier; D Jacobs; S Muguet; E Depla; G Inchauspé
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization.

Authors:  A Fournillier; E Depla; P Karayiannis; O Vidalin; G Maertens; C Trépo; G Inchauspé
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

8.  DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.

Authors:  Adriana S Azevedo; Anna M Y Yamamura; Marcos S Freire; Gisela F Trindade; Myrna Bonaldo; Ricardo Galler; Ada M B Alves
Journal:  PLoS One       Date:  2011-07-11       Impact factor: 3.240

9.  The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.

Authors:  Adriana S Azevedo; Antônio J S Gonçalves; Marcia Archer; Marcos S Freire; Ricardo Galler; Ada M B Alves
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

10.  Cooperation between CD4+ T Cells and Humoral Immunity Is Critical for Protection against Dengue Using a DNA Vaccine Based on the NS1 Antigen.

Authors:  Antônio J S Gonçalves; Edson R A Oliveira; Simone M Costa; Marciano V Paes; Juliana F A Silva; Adriana S Azevedo; Marcio Mantuano-Barradas; Ana Cristina M A Nogueira; Cecília J Almeida; Ada M B Alves
Journal:  PLoS Negl Trop Dis       Date:  2015-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.